ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 1407 • ACR Convergence 2023

    Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA

    Dafne Capelusnik1, Sofia Ramiro2, Elena Nikiphorou3, Walter P. Maksymowych4, Marina Nighat Magrey5, Helena Marzo-Ortega6 and Annelies Boonen7, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3King's College London, London, United Kingdom, 4University of Alberta, Edmonton, AB, Canada, 5Case Western Reserve University, University Hospitals, Cleveland, OH, 6NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 7Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands

    Background/Purpose: Presenteeism is associated with lower work satisfaction and future sick leave in axial spondyloarthritis (axSpA). It is generally assessed as a continuous variable; however,…
  • Abstract Number: 2213 • ACR Convergence 2023

    Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach

    Imke Redeker1, Styliani Tsiami2, Jan Eicker3, Uta Kiltz4, David Kiefer2, Ioana Andreica5, Philipp Sewerin2 and Xenofon Baraliakos6, 1Ruhr Universität Bochum, Bochum, Germany, 2Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 3Rheumazentrum Ruhrgebiet Herne and Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: In axial spondyloarthritis (axSpA), early diagnosis plays a key role in preventing disease progression. However, a validated diagnostic algorithm does not exist, while classification…
  • Abstract Number: 0090 • ACR Convergence 2023

    Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis

    Addison Pacheco1, Michael Tang1, Sinead Maguire2, Melissa Lim1, Fataneh Tavasolian3, Zoya Qaiyum4 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Axial spondyloarthritis (AxSpA) is an inflammatory disease that predominantly affects the spine and the sacroiliac joints. Dysregulation of Type 3 immunity has been implicated…
  • Abstract Number: 0531 • ACR Convergence 2023

    Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis

    Inbeom Kwon1, bora nam2, Nayeon Choi3, Ji-Hui Shin2, Seunghun lee4 and Tae-Hwan Kim2, 1Department of Medicine, Hanyang University College of Medicine, Seoul, South Korea, 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: To investigate the effects of anti-tumor necrosis factor (anti-TNF) treatment on lipid profiles and identify risk factors for elevated total cholesterol (TC) after the…
  • Abstract Number: 1385 • ACR Convergence 2023

    Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers

    Joerg Ermann1, Stephanie Sinnappan2 and Alexandra Forte3, 1Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Memorial Sloan Kettering Cancer Center, New York, NY

    Background/Purpose: Several sets of treatment recommendations for axial spondyloarthritis and ankylosing spondylitis (axSpA/AS) have been published. Clinical practice guidelines are not followed consistently by health…
  • Abstract Number: 1408 • ACR Convergence 2023

    Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort

    Ji In Jung1, Ju Yeon Kim2, Jin Kyun Park3, Eun Young Lee3, Eun Bong Lee2 and Jun Won Park2, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea, 3Seoul National University College of Medicine, Seoul, South Korea

    Background/Purpose: Although previous studies suggested that physical functioning is largely driven by disease activity in patients with spondyloarthritis (SpA), its relationship to radiographic progression has…
  • Abstract Number: 2214 • ACR Convergence 2023

    Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis

    Abhijeet Danve1, Maureen Dubreuil2, Swetha Ann Alexander3, Yuliya afinogenova4, Mohamad Bittar5, Alyssa Grimshaw6, Liana Fraenkel7, Michael LaValley8, Anand Kumthekar9, Jean liew10, Marina Nighat Magrey11, Vikas Majithia12, Sali Merjanah13, Hillary Norton14, Jessica A Walsh15 and Atul Deodhar16, 1Yale University School of Medicine, Glastonbury, CT, 2Department of Rheumatology, Boston University School of Medicine, Milton, MA, 3University of Utah Health, Salt Lake City, UT, 4Yale, Hamden, CT, 5The University of Tennessee Health Science Center, Memphis, TN, 6Yale University, New Haven, CT, 7Berkshire Health Systems, Lenox, MA, 8Boston University School of Public Health, Arlington, MA, 9Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 10Boston University, Boston, MA, 11Case Western Reserve University, University Hospitals, Cleveland, OH, 12Mayo Clinic Florida, Jacksonville, FL, 13Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 14Inspire Santa Fe Rheumatology, Santa Fe, NM, 15Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, 16Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
  • Abstract Number: 0092 • ACR Convergence 2023

    Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion

    Michael Tang1, Zoya Qaiyum2, Melissa Lim1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada

    Background/Purpose: Sustained chronic inflammation in the spine and of the sacroiliac joints is a key feature in Ankylosing Spondylitis (AS). A central role of CTL…
  • Abstract Number: 0532 • ACR Convergence 2023

    Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis

    bora nam1, Nayeon Choi2, Bon San Koo3, Jiyeong Kim2, Ji-Hui Shin1, Seunghun lee4, kyung bin Joo4 and Tae-Hwan Kim1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea, 3Inje University Seoul Paik Hospital, Seoul, South Korea, 4Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Anti-tumor necrosis factor (TNF) agents have proven to be effective in treating Ankylosing spondylitis (AS). However, a significant number of patients discontinue or switch…
  • Abstract Number: 1386 • ACR Convergence 2023

    Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis

    Huseyin Berk Degirmenci1, Christine E. Peloquin2, Sara Lodi2, Pedro Machado3, S. Reza Jafarzadeh4, Tuhina Neogi5, Lianne Gensler6, Maureen Dubreuil7 and Jean Liew2, 1St. Elizabeth's Medical Center, Boston, MA, 2Boston University, Boston, MA, 3Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, 4Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 7Department of Rheumatology, Boston University School of Medicine, Milton, MA

    Background/Purpose: Although current axial spondyloarthritis (axSpA) management guidelines do not address opioid use for chronic pain, available data show that opioid use is common among…
  • Abstract Number: 1409 • ACR Convergence 2023

    Analysis of Soluble Biomarkers in Axial Spondyloarthritis

    Caroline Bauchiero1, Stephanie Sinnappan2 and Joerg Ermann3, 1Brigham and Women's Hospital, Boston, MA, 2Columbia University, New York, NY, 3Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…
  • Abstract Number: 2219 • ACR Convergence 2023

    Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis

    Dafne Capelusnik1, Elena Nikiphorou2, Annelies Boonen3, Désirée van der Heijde4, Robert BM Landewé5, Astrid van Tubergen6 and Sofia Ramiro4, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2King's College London, London, United Kingdom, 3Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, 6Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands

    Background/Purpose: In the context of the recent update of the ASAS core outcomes set (COS), the preferred comparative validity of the measurement instruments to assess…
  • Abstract Number: 0202 • ACR Convergence 2023

    Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)

    Tal Gazitt1, Noa Hayat2, Amir Haddad2, Joy Feld3, Nili Stein2, Idit Lavi2, Ilan Feldhamer4, Arnon Dov Cohen5, Walid Saliba2 and Devy Zisman2, 1Carmel Hospital, Haifa, Israel, 2Carmel Medical Center, Haifa, Israel, 3Carmel and Zvulun Medical Centre, Haifa, Israel, 4Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, 5Ben-Gurion University of the Negev, Beer-Sheva, Israel

    Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
  • Abstract Number: 0535 • ACR Convergence 2023

    Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex

    EA TROY1, ZT Chan1, WL GALLANTER2, EM Adams3, Mina Al-Awqati2 and Huan Chang1, 1University of Illinois at Chicago; Jesse Brown VA Medical Center, Chicago, IL, 2University of Illinois at Chicago, Chicago, IL, 3Jesse Brown VA Medical Center, Chicago, IL

    Background/Purpose: Ankylosing spondylitis (AS) is estimated to affect up to 1,647,500 Americans, resulting in significant disability and lost productivity for affected individuals. Biologic medications reduce…
  • Abstract Number: 1390 • ACR Convergence 2023

    Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study

    Asmir Vodencarevic1, Jan Brandt-Juergens2, Daniel Peterlik1, Benjamin Gmeiner1 and Uta Kiltz3, 1Novartis Pharma GmbH, Nürnberg, Germany, 2rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients suffering from ankylosing spondylitis (AS) in randomized clinical trials [1]. There is only limited…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology